%3Aformat(webp)&w=3840&q=75)
Västra Hamnen Corporate Finance
Capital Markets Transactions and M&As
Recent research
%3Aformat(webp)&w=3840&q=75)
Crunchfish: 2025 - time to deliver
Following our last comment, we still await Crunchfish’s commercial breakthrough. The company is in discussions with several Indian counterparties, including the Reserve Bank of India (RBI), the National Payments Corporation of India, major banks and digital wallet providers. The RBI is currently upgrading the Digital Rupee to a value-based token system, starting with online payments. We believe the discussions will advance once the parties start to focus on the offline part of the upgrade. According to the report, this will take place in Q2. This has led us to lower our sales forecast near-term, leading to an adjustment of our fair value to SEK 5.88 (7.42) per share.
%3Aformat(webp)&w=3840&q=75)
Precise Biometrics: Scanning for higher growth
Precise Biometrics is a Lund-based company that develops software for biometric recognition in various applications. 2024 was a turnaround year for Precise Biometrics, reporting a steady improvement in profitability. The stock market noted the development, Precise Biometrics was the best-performing share on the Swedish main list last year, posting a 350-per cent rise. Our growth prospects imply a fair value of SEK 7.25 per share.
%3Aformat(webp)&w=3840&q=75)
CombiGene: Making place for new ventures
After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities and lay off personnel. In the light of the operational and business changes made, the company has issued a notice of an extraordinary general meeting to be held on February 20, 2025. The EGM will decide on a new board member and also on authorising the board to decide on the issuance of new shares, warrants or convertibles, with or without deviation from the shareholders’ preferential rights. To provide further insights, Västra Hamnen Corporate Finance reached out to the newly appointed chairman Luca Di Stefano.
%3Aformat(webp)&w=3840&q=75)
ProstaLund: Study shows benefits of CoreTherm
The scientific journal Journal of Nephrology, Urology and Andrology has published a registry study that shows advantages of ProstaLund's treatment method CoreTherm Concept for benign prostatic hyperplasia compared to the standard treatment transurethral resection (TURP). CEO Anders Kristensson answers five questions from Västra Hamnen.
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75){kind=logo}
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
%3Aformat(webp)&w=3840&q=75)
Market Focus
Market focus is our service for stock analysis of small and medium-sized listed companies. The service contributes to increased turnover in the share by increasing investors' awareness of the company and attention to current events. All our analyses are listed below.
Market Focus
Register for Market Focus updates
About us
We help our customers grow
Västra Hamnen Corporate Finance is an independent securities company that provides advice in connection with corporate transactions.
%3Aformat(webp)&w=3840&q=75)
"We love small companies and do our best every day to be their first choice in connection with listing processes and capitalizations."